Antiviral therapy of chronic hepatitis B patients resistant to lamivudine / 中华实验和临床病毒学杂志
Chinese Journal of Experimental and Clinical Virology
;
(6): 395-397, 2005.
Artigo
em Chinês
| WPRIM
| ID: wpr-332997
ABSTRACT
<p><b>BACKGROUND</b>To evaluate the efficacy of alpha-2b interferon alone or combined with alpha1-thymosin in treatment of patients with chronic hepatitis B (CHB) resistant to lamivudine.</p><p><b>METHODS</b>Sixty six patients with CHB resistant to lamivudine were enrolled and randomized into treatment group A, treatment group B and control group. In the treatment group A 26 cases, after giving interferon-alpha alone for 1 month, lamivudine was withdrawn and continuously treated with interferon-alpha for 5 months. In the treatment group B 10 cases, after treatment with interferon-alpha and thymosin-alpha1 for 1 month, lamivudine was withdrawn and continuously treated with interferon-alpha and thymosin-alpha1 for 5 months. In control group (30 cases), after lamivudine was directly withdrawn, no anti-virus drug was given. Hepatic function tests and serum virological index were detected at regular intervals in all patients.</p><p><b>RESULTS</b>Normalization rate of hepatic function, HBV DNA seroconversion rate and HBeAg/HBeAb seroconversion rate in two treatment groups were significantly higher than those in control group.</p><p><b>CONCLUSION</b>The study suggested that interferon-alpha alone or combined with thymosin-alpha1 in treatment of patients with chronic hepatitis B resistant to lamivudine showed a beneficial effect.</p>
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Antivirais
/
Farmacologia
/
Timosina
/
Virologia
/
Sangue
/
Proteínas Recombinantes
/
DNA Viral
/
Vírus da Hepatite B
/
Resultado do Tratamento
/
Interferon-alfa
Tipo de estudo:
Ensaio Clínico Controlado
Limite:
Adolescente
/
Adulto
/
Feminino
/
Humanos
/
Masculino
Idioma:
Chinês
Revista:
Chinese Journal of Experimental and Clinical Virology
Ano de publicação:
2005
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS